Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.57 |
| ▸ | ABCB1 | P08183 | 5/20 | 0.50 |
| ▸ | ABCC1 | P33527 | 3/20 | 0.50 |
| ▸ | DRD2 | P14416 | 3/20 | 0.47 |
| ▸ | DRD4 | P21917 | 3/20 | 0.47 |
| ▸ | DRD3 | P35462 | 3/20 | 0.47 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.45 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3065720 | 0.88 | HRH3 (0.59) | HRH3ABCB1ABCC1DRD2DRD4 | |
| SCHEMBL3070986 | 0.87 | HRH3 (0.58) | HRH3ABCB1ABCC1DRD2DRD4 | |
| SCHEMBL3085367 | 0.84 | HRH3 (0.54) | HRH3ABCB1ABCC1 | |
| SCHEMBL3071421 | 0.82 | ABCB1 (0.55) | HRH3ABCB1ABCC1DRD2DRD4 | |
| SCHEMBL3074570 | 0.79 | HRH3 (0.55) | HRH3ABCB1ABCC1DRD2DRD4 | |
| SCHEMBL3082257 | 0.78 | HRH3 (0.70) | HRH3ABCB1ABCC1DRD2DRD4 | |
| SCHEMBL3084148 | 0.77 | HRH3 (0.55) | HRH3ABCB1ABCC1DRD2DRD4 | |
| SCHEMBL5188047 | 0.75 | ACP1 (0.43) | ABCB1ABCC1 | |
| SCHEMBL3066616 | 0.75 | HRH3 (0.55) | HRH3 | |
| SCHEMBL2764403 | 0.74 | DRD2 (0.49) | HRH3ABCB1ABCC1DRD2DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080275046-A1 | Compounds Comprising an Oxazole or Thiazole Moiety, Processes for Making Them, and Their Uses | UCB PHARMA, S.A. (BE) | 2008-11-06 | — | — | US | claimed |
| US-7790720-B2 | Compounds comprising an oxazole or thiazole moiety, processes for making them, and their uses | UCB PHARMA, S.A. (BE) | 2010-09-07 | — | — | US | disclosed |
| US-20080275046-A1 | Compounds Comprising an Oxazole or Thiazole Moiety, Processes for Making Them, and Their Uses | UCB PHARMA, S.A. (BE) | 2008-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275046-A1 | Compounds Comprising an Oxazole or Thiazole Moiety, Processes for Making Them, and Their Uses | OXER1, OXTR, OGFR | HRH3 4/4885ABCB1 500/4885ABCC1 572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.